Cao Lei, Li Rui, Wu Xudong
State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Cancer Institute and Hospital, Department of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
Front Mol Biosci. 2021 Mar 12;8:657150. doi: 10.3389/fmolb.2021.657150. eCollection 2021.
The interplay between cancer genome and deregulated epigenomic control is critical for cancer initiation and progression. (Additional Sex combs-like 1) is frequently mutated in tumors especially myeloid malignancies. However, there remains a debate whether the mutations are loss or gain-of-function. Mechanistically, ASXL1 forms a complex with BAP1 for the erasure of mono-ubiquitylation at lysine 119 on Histone H2A (H2AK119ub1), a well-known histone mark associated with transcription repression. Unexpectedly, this de-ubiquitylation complex has been genetically defined as a Polycomb Repressive complex though the regulatory mechanisms are elusive. In this review, we will discuss about the functions of ASXL1 in malignancies and reconcile seemingly paradoxical effects of ASXL1 or BAP1 loss on transcription regulation.
癌症基因组与失调的表观基因组控制之间的相互作用对于癌症的发生和发展至关重要。(额外性梳状蛋白样1)在肿瘤尤其是髓系恶性肿瘤中经常发生突变。然而,关于这些突变是功能丧失还是功能获得仍存在争议。从机制上讲,ASXL1与BAP1形成复合物,用于消除组蛋白H2A赖氨酸119处的单泛素化(H2AK119ub1),这是一种与转录抑制相关的著名组蛋白标记。出乎意料的是,尽管调控机制尚不清楚,但这种去泛素化复合物在遗传学上已被定义为一种多梳抑制复合物。在这篇综述中,我们将讨论ASXL1在恶性肿瘤中的功能,并协调ASXL1或BAP1缺失对转录调控看似矛盾的影响。